The Impact of Obesity on Treatment Outcomes in Patients with Hormone Receptor–Positive HER2-Negative Metastatic Breast Cancer Receiving CDK 4/6 Inhibitors
While BMI-defined obesity showed slight PFS improvement with CDK 4/6 inhibitors and endocrine therapy, using VAT to define obesity revealed significant PFS gains. This highlights the need for further research on biomarker to clarify the role of adiposity in MBC, which may differ from its impact in EBC.
Authors
- Ji Hyung Hong (ORCID: https://orcid.org/0000-0002-0492-3959)
- Chai Hong Rim (ORCID: https://orcid.org/0000-0001-7431-4588)
- Hee Kyung Ahn (ORCID: https://orcid.org/0000-0001-7786-7233)
- Hyun-Young Shin
- Y.S. Jung
Institutions
- Korea University Medical Center (KR)
- Samsung Medical Center (KR)
- EP Analytics (United States) (US)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Sungkyunkwan University (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2025-04-15
- DOI
- https://doi.org/10.4143/crt.2025.110
- Citations
- 2
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Fonds National de la Recherche Luxembourg
- Catholic University of Korea